CellCentric nets $220M Read in browser

Thank you for reading, dupa dupackia! basic Subscription UPGRADE

M T Wed Th F 6 May, 2026

US biopharma still leads the world in high-risk drug development, but the road from innovation to access has never been harder to predict. Hear from top executives and investors on how they’re navigating what’s next. Join us.

presented by Bio­con’s Bold In­te­gra­tion: Uni­fy­ing Biosim­i­lars and Gener­ics to Re­de­fine Glob­al Af­ford­able Ac­cess

news Novo Nordisk's first quarter in four words: Pills, pricing, payments and pressure Bayer dips toes back into pharma M&A to buy Perfuse Therapeutics CellCentric raises $220M to get multiple myeloma pill to market Intercept's next-gen FXR agonist fails Phase 2 in latest setback for Italian-owned pharma

May 12 10:30 am ET Rules of engagement: How G3BP2 paves the way to rationalize novel degrons sponsored by Thermo Fisher May 20 11:00 am ET Application of Simple Western to analysis of antibody target affinity and specificity sponsored by Bio-Techne

ASCO is about to deliver some make-or-break cancer data. Join us to figure out which pipeline bets will pay off. Get your spot now.

ENDPOINTS PHARMA Pfizer's Albert Bourla on mega-merger prospects: 'No' •  Pfizer cuts final Trillium-related program, but R&D spend jumps on cancer, obesity studies BioNTech to scale down manufacturing, over 1,800 jobs on the line Swiss manufacturing, biotech industry so far unfazed by geopolitics

in case you missed it 1. Exclusive: One cancer survivor's super poop is behind microbiome startup's $48M raise 2. Updated: Madrigal extends MASH deal streak with Arrowhead drug that J&J didn't want 3. J&J's IBD combo fails Phase 2 studies, but will move into pivotal testing 4. News Briefing Second life for a gene therapy; Takeda passes Phase 2/3 test; UK cancer biotech's $83M raise 5. Cytokinetics succeeds where Bristol Myers failed in heart muscle disease 6. Vertex drops mRNA cystic fibrosis program over 'tolerability' issues 7. FDA halts publication of studies on covid, shingles vaccines 8. In a milestone for ALS, a treatment helps some patients improve